Grapevine
Founded 2020 · 27 employees on LinkedIn · 6 known investors
Grapevine is a medical supply procurement service that negotiates prices, expands vendor networks, and reroutes orders to help clinics avoid overpaying and stay in stock. It serves medical practices such as dermatology, oncology, and rheumatology clinics.
Also known as Grapevine Technologies
Investors · 6
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$4.1M disclosed across 1 of 3 rounds · 2023–2026
- Undisclosed amountundisclosed roundMar 2026Source ↗
- $4.1MraisedMar 2026 · 3 sources
Kae Capital, Peak XV, Screwvala family office
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Grapevine (Grapevine Technologies) operates software that acts as a purchasing agent for healthcare buyers rather than as a marketplace or distributor. The platform compares vendors, prices and supply routes in real time and applies that visibility to the ordering process for medical practices, with four core capabilities described on the company site: pricing negotiation on the items a practice already buys, vendor network expansion to widen sourcing options, smart rerouting so backordered items are automatically substituted with an available alternative from another vendor, and workflow tooling intended for use across a practice's teams.
Customers are clinical practices in specialties including dermatology, oncology, rheumatology, orthopedic surgery and physical therapy/rehabilitation, ranging from single-location clinics with one to three procurement staff to groups with more than 100 locations and 40-plus procurement staff. A published case study covering The Orthopedic & Sports Medicine Institute (OSMI), a two-location orthopedic and sports-medicine practice, describes a custom catalog built by Grapevine, negotiated pricing across ten vendors, $20.7K of savings since January 2025 on $168.9K of annual spend (13% lower than before), and 99.6 hours of staff time saved per year. Grapevine also cites customer-to-customer referrals as a growth channel, listing named practices referred by staff at existing customers.
The company presents its work as a response to price opacity and fragility in medical supply distribution, arguing that the prices vendors show buyers are not the only prices available and that single shortages can disrupt clinical operations.
Founding story
Co-founder and CEO Luká Yancopoulos traces Grapevine to the COVID-19 pandemic, when healthcare workers — including his mother — faced shortages and unexplained prices. He and his team used publicly available FDA data to trace how medical supplies actually moved and to connect healthcare practices with suppliers during the early pandemic, identifying waste embedded in process, markups presented as commission, and complexity that obscured pricing. That project became the basis for the company.
Business model
Grapevine sells software and procurement services directly to medical practices. According to the OSMI case study, there is no upfront platform fee: the company charges nothing to start and instead earns a percentage of the savings it generates for the customer, a model positioned against competing procurement platforms that charge large upfront fees without guaranteeing savings.
Performance-based: zero cost to begin, with Grapevine taking a small percentage of the savings achieved on customer supply spend; if no savings are achieved the customer pays nothing.
Traction
The website reports customer savings including $2.85M since December 2023 at a 100+ location oncology group with a 40+ person procurement team, $195K and $150K since December 2024, $133K since March 2025, $77.4K since September 2023 at a single-location dermatology practice, $20.7K at a five-location orthopedic practice and $11.99K at a single-location dermatology clinic, with cited savings rates of 45-54%. The OSMI case study reports $20.7K saved since January 2025 (about $2,074 monthly) and 99.6 hours saved per year. Referral-driven accounts listed include Minars Dermatology ($34.6K), Peninsula Dermatology ($133.3K), Santa Monica Dermatology ($13.3K), Advanced Dermatology Associates ($12.4K), Tucson Dermatology ($5.5K) and Hampton Roads Orthopaedics Spine & Sports Medicine ($11.1K).
Latest developments
A case study published on the company site covers savings at The Orthopedic & Sports Medicine Institute accrued since January 2025, and site-wide savings counters reference customer engagements beginning as recently as March 2025.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Grapevine positions itself as an agent for healthcare buyers rather than a marketplace or middleman, in a medical supply market described in press coverage as worth $200 billion. Its stated ambition is to reduce practice spending on medical devices, drugs and supplies by more than 50%, which the CEO has framed as potentially returning a quarter trillion dollars annually to the U.S. healthcare system.
No upfront cost and fees contingent on realized savings; sourcing across an expanded vendor network rather than a single distributor relationship; automatic substitution of backordered items; and item-level price transparency across multi-site groups, which customers say exposes cases where one clinic pays more than another for the same item.
Technology
Software that maintains visibility across vendors, prices and supply routes in real time and acts as an intelligent purchasing agent on behalf of buyers. It builds practice-specific catalogs with item-level savings, automatically substitutes backordered items with available alternatives from other vendors, and uses data on how supplies move and are used — originally derived from publicly available FDA data — to identify inefficiencies before and after supplies reach a practice. The CEO has described using tracking and predictive approaches to anticipate supply needs and to surface overuse or misuse of supplies.
Go-to-market
Direct sales through account executives, supported by demo requests and self-signup on the website, an onboarding and implementation team, and customer-experience staff. Voluntary referrals from existing customers to other practices are highlighted as a source of new business, with named referrers and the savings achieved at referred practices. The company also maintains a newsroom of press and podcast coverage.
Outpatient and specialty medical practices and clinic groups, including dermatology (medical, cosmetic, aesthetics and plastic surgery), oncology and cancer treatment, rheumatology, orthopedic surgery, and physical therapy and rehabilitation; customers range from single-site clinics to networks of over 100 locations.
Geography
Headquartered in New York City, with most customer-facing, design and engineering staff based in New York and a data operations team based in the Philippines. Customers are U.S. medical practices.
History
The effort began as a pandemic-era project using public data to match healthcare practices with scarce supplies, then transitioned into a business. Press coverage of the company dates from at least 2022, with a Forbes-style profile in August 2023 describing how it helps healthcare buyers save money in a $200 billion market, a podcast appearance on the AlchemistX Innovators Inside show in September 2024, and a November 2024 piece on savings delivered to The Oncology Institute. Customer savings counters on the site reference start dates from September 2023 through March 2025.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsSeason six premiere episode discussing Grapevine's COVID-era origins, use of publicly available data, and goal of cutting practice supply spending by more than 50%.
Article by Amit Chowdhry listed in the company newsroom.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Grapevinego-grapevine.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Grapevine do?
- Grapevine is a healthcare procurement platform that negotiates prices and reroutes orders so medical practices spend less on supplies.
- Who are Grapevine's investors?
- Grapevine's investors include The MBA Fund, Atlas Venture, Kae Capital, Peak XV Partners.
- How much funding has Grapevine raised?
- Grapevine has disclosed $4.1M raised across 1 of its 3 known rounds.